Journal of the American Academy of Child & Adolescent Psychiatry
Volume 46, Issue 9 , Pages 1222-1225, September 2007

Antidepressant Management in the Context of Suicidal Ideation

Dr. Emslie is with the Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas; Dr. Waslick is with the Division of Child Behavioral Health, Baystate Health, and Tufts University School of Medicine, Boston; Dr. E. Weller is with the Departments of Psychiatry and Pediatrics, University of Pennsylvania, and Children's Hospital of Philadelphia; Dr. Kloos is with Jefferson University, Philadelphia; Dr. R. Weller is with the University of Pennsylvania, Philadelphia; Dr. Kratochvil is with the Department of Psychiatry, University of Nebraska Medical Center, Omaha.

Accepted 13 April 2007.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 12.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This is a case vignette created to exemplify a complex clinical problem and does not refer to any specific patient.This column aims to discuss practical approaches to everyday issues in pediatric pharmacotherapy. The cases and discussions specifically target aspects of clinical care related to psychopharmacology for which we do not have adequate applicable controlled trials. Given the need to address symptoms in youths with complex, severe, and comorbid disorders, recommendations are likely to be off-label from the perspective of the U.S. Food and Drug Administration. We fully appreciate that for virtually all disorders, medication is only one aspect of comprehensive care. This column focuses primarily on psychopharmacologic management. Although it is important that clinicians address psychosocial issues in the evaluation and treatment of their patients, such discussion is beyond the specific scope of this feature. These are not meant to be practice guidelines, but rather examples of thought processes that may go into pharmacotherapy decision making.Disclosure: Dr. Emslie receives research support from Eli Lilly, Organon, and Forest Laboratories; is a consultant for Eli Lilly, GlaxoSmithKline, Forest, Wyeth-Ayerst, and Pfizer; and is on the speakers' bureau of McNeil. Dr. E. Weller has been a consultant for or participated in studies supported by AstraZeneca, Johnson & Johnson, Jazz, and Otsuka. Dr. Kratochvil receives grant support from Eli Lilly, McNeil, Shire, Abbott, and Cephalon; is a consultant for Eli Lilly, Cephalon, Organon, AstraZeneca, Abbott, and Pfizer and a member of the Eli Lilly speakers' bureau; and has received study drug for an NIMH-funded study from Eli Lilly. The other authors have no financial relationships to disclose.

PII: S0890-8567(09)61942-0

doi:10.1097/chi.0b013e3180ca7cc5

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 46, Issue 9 , Pages 1222-1225, September 2007

Article Tools